businesspress24.com - Avid Bioservices to Participate at Upcoming Life Sciences Industry Conferences
 

Avid Bioservices to Participate at Upcoming Life Sciences Industry Conferences

ID: 1474792

(firmenpresse) - TUSTIN, CA -- (Marketwired) -- 12/09/16 -- Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) (NASDAQ: PPHMP), today announced that the company will attend and participate at two upcoming life sciences industry conferences. The company will host a corporate booth in the exhibit hall at KNect365 Life Sciences'' Antibody Engineering & Therapeutics conference. In addition, Pete Gagnon, Avid''s vice president, process sciences, will present a case study on innovative applications for antibody manufacturing processes at the 16th Annual Global Bioproduction Summit.

Details of these activities are as follows:

KNect365 Life Sciences'' Antibody Engineering & Therapeutics: December 11-15, 2016, San Diego, CA

Avid will host corporate booth #209 showcasing the company''s comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. These include a variety of innovative processes for generating a broad range of biopharmaceutical product types such as monoclonal antibodies, highly-glycosylated recombinant proteins and enzymes, among others. These capabilities also extend to the manufacture of biosimilar products and are designed to support the overall ongoing growth of the company''s contract manufacturing business.

16th Annual Global Bioproduction Summit: December 12-13, 2016, San Diego, CA

Mr. Gagnon will present a case study highlighting the importance of managing keystone contaminants in downstream processing. The presentation, which will take place from 10:55 - 11:25 a.m. (Pacific) on Monday, December 12th, will detail streamlined manufacturing processes for removing chromatin from cell culture harvests to enable improved purification process economics and product quality. The content of this case study showcases the industry-leading manufacturing expertise that Avid offers to its clients.





For additional details on these events, please visit: and .

Avid Bioservices provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 15 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid''s services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. For more information about Avid, please visit .

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of patients by delivering high quality pharmaceutical products through its contract development and manufacturing organization (CDMO) services and through advancing and licensing its investigational immunotherapy and related products. Peregrine''s in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. (), which provides development and biomanufacturing services for both Peregrine and third-party customers. The company is also working to evaluate its lead immunotherapy candidate, bavituximab, in combination with immune stimulating therapies for the treatment of various cancers, and developing its proprietary exosome technology for the detection and monitoring of cancer. For more information, please visit .



Kelly Pisarev Lord
Avid Bioservices, Inc.
(800) 987-8256

Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401


Tim Brons (Media)
Vida Strategic Partners
415-675-7402

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Sermonix Pharmaceuticals Signs Exclusive Licensing Agreement to Further Explore Lasofoxifene for Breast Cancer Treatment
Corcept Therapeutics Announces Encouraging Results of Phase 1/2 Trial of Mifepristone Plus Eribulin in Triple-Negative Breast Cancer
Bereitgestellt von Benutzer: Marketwired
Datum: 09.12.2016 - 07:05 Uhr
Sprache: Deutsch
News-ID 1474792
Anzahl Zeichen: 4076

contact information:
Contact person:
Town:

TUSTIN, CA


Phone:

Kategorie:

Biotech


Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:


Diese Pressemitteilung wurde bisher 280 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Avid Bioservices to Participate at Upcoming Life Sciences Industry Conferences
"
steht unter der journalistisch-redaktionellen Verantwortung von

Avid Bioservices (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Avid Bioservices



 

Who is online

All members: 10 563
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 63


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.